Our previous study demonstrated that a cream-based sericin formulation reduces the severity of psoriasis through Th17 cells by interfering with the Janus kinase (JAK)-signal transducer and the activator of transcription (STAT) pathway5. The gene discussed is SOAT1; the disease is psoriasis.